Changchun high-tech unit secures exclusive allergen immunotherapy rights

Changchun High & New Technology Industry Group's subsidiary, GeneScience Pharmaceutical, has partnered with Denmark's ALK-Abelló A/S to collaborate on three allergen-specific immunotherapy (AIT) products for the Chinese market. GeneScience Pharmaceutical will obtain exclusive rights to ALK's house dust mite (HDM) allergen-specific immunotherapy products in mainland China, including one subcutaneous injection, one sublingual tablet, and one skin prick test kit, with the cooperation effective until December 31, 2039.

GeneScience Pharmaceutical will make an upfront payment of €32.7m for commercialization rights. Additionally, milestone payments of €40m are tied to regulatory approval progress for ACARIZAX® in adult, adolescent, and pediatric indications in China. The subsidiary will also pay up to €105m in sales-based milestones and cover the majority of phase III bridging clinical research and registration costs for adult and adolescent indications.

GeneScience Pharmaceutical is set to take over sales and market promotion of ALK's existing cooperative products in China starting October 1, 2025. The company cautioned investors that the final payment of milestone amounts is subject to certain conditions and domestic clinical trials and registration are still pending.